Pharmacists in Oregon Will Prescribe Birth Control in 2016 (Video)
A new birth control law in Oregon is set to go into effect on Friday.
The new law will allow pharmacist to...
Gene editing halts Duchenne muscular dystrophy, says new Research
A gene editing technique has shown promise in treating Duchenne muscular dystrophy (DMD), the most common and severe form of muscular...
Zika Virus: Puerto Rico Reports First Case, Report
Health officials in Puerto Rico reported the island’s first case of Zika, a mosquito-borne virus recently linked to the rise of...
Couple Clones Deceased Dog For for $100000 (Video)
A British couple recently spent $100,000 to have their deceased dog cloned into a little Boxer. The history-making puppy was born...
Radiation during heart tests higher for patients in US, says new Research
Myocardial perfusion imaging, or nuclear stress tests, are considered essential for the diagnosis and management of coronary artery disease, but radiation...
Weight Loss Surgery May Weaken Bones, study shows
Certain types of bariatric or weight loss surgery aren't risk-free according to a recently conducted Taiwan-based study. Some surgical procedures may...
Losing weight in the new year, New research
New research conducted by scientists at the University of Texas at Austin shows that within five years, doctors may have diets...
Uganda facing HIV drugs shortage, govt seeks cash for imports
KAMPALA Uganda is suffering a shortage of imported drugs to treat HIV victims due to a weak currency and insufficient foreign exchange but the government is raising funds to cover the shortfall, a senior finance ministry official said.Health activis...
FDA lifts clinical hold on Advaxis’ cancer compounds
Drug developer Advaxis Inc said on Wednesday the U.S. Food and Drug Administration had lifted a clinical hold on three of its experimental cancer therapies, sending the company's shares up as much as 38 percent.The U.S. health regulator had in Octob...
Novartis hires Harvard star to plug gaps in cancer drug arsenal
ZURICH Pharmaceuticals giant Novartis is pinning its hopes on a 43-year-old Harvard cancer research star to help fill gaps in its immuno-oncology arsenal after "missing the boat" on some promising therapies.James "Jay" Bradner, from Harvard's Dana-F...